FIELD: organic chemistry, medicine, narcology, pharmacy.
SUBSTANCE: invention relates to a sustained-release medicinal formulation designated for reducing abuse to nicotine. The medicinal formulation comprises 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]hexadeca-2(11),3,5,7,9-pentaene or its pharmaceutically acceptable salt that is administrated in patient at the rate less 6 mg/h that corresponds to at least 0.1 mg of indicated compound for 24 h. Also, invention relates to the sustained-release medicinal formulation comprising low dose of indicated medicinal substance. Method for using involves oral administration of the sustained-release medicinal formulation at the first stage for period from about 1 day to about 30 days followed by administration the sustained-release medicinal formulation at the second stage. Invention provides reducing abuse for nicotine and simultaneous decreasing appearance of nausea frequency as adverse effect.
EFFECT: valuable medicinal properties of composition.
10 cl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SOLID DOSAGE FORMS OF PALLBOCYCLOB | 2016 |
|
RU2686840C1 |
| DRY GRANULATED AZITHROMICINE COMPOSITIONS | 2003 |
|
RU2283092C2 |
| NEW COMPOSITION OF LAPATINIB AS A SOLID DOSAGE FORM FOR ORAL USE AND A METHOD OF ITS MANUFACTURE | 2019 |
|
RU2821950C2 |
| STABLE PHARMACEUTICAL PREPARATION CONTAINING AMLODIPINE BENZYLATE AND ATENOLOL | 1998 |
|
RU2188636C2 |
| PHARMACEUTICAL FORMULATION OF ATORVASTATIN | 2004 |
|
RU2325903C2 |
| TAMZULOSIN TABLETS | 2002 |
|
RU2311903C2 |
| PROLONGED-RELEASE ORAL PHARMACEUTICAL MEDICINAL FORM | 1998 |
|
RU2214232C2 |
| MATRIX TABLET WITH MODIFIED NERAMEXANE RELEASE | 2006 |
|
RU2422135C2 |
| PHARMACEUTICAL COMPOSITION WITH ANTICONVULSIVE AND PSYCHOTROPIC ACTION | 2007 |
|
RU2342144C1 |
| METHODS FOR AZITROMICINE WET GRANULATION | 2002 |
|
RU2283651C2 |
